Retatrutide Nominal vs. Usable Vial Volume: The 0.1 mL Gap

Nominal volume describes the glass, not the contents. When a retatrutide listing quotes a vial as “2 mL” or “3 mL,” that figure names the container blank the lyophilized cake was filled into. Usable volume is a different quantity: the diluent you add, minus whatever stays in the vial heel, the stopper face, and the needle hub after the last draw. To compare retatrutide vial nominal volume versus usable volume claims, ignore the container designation entirely and convert each listing to recoverable millilitres at a stated reconstitution volume, then divide labeled peptide mass by that number.

What is a listing actually claiming when it says “3 mL vial”?

A nominal designation is a container spec. It tells you the brimful capacity of the glass and, by extension, roughly how much diluent the vial will accept without the stopper fighting you on reinsertion. It says nothing about how much peptide is inside, and nothing about how much liquid comes back out.

Lyophilized retatrutide ships as a dry cake, so the vial arrives with almost no liquid in it at all. The number that governs everything downstream is the labeled peptide mass in milligrams, which is why fill volume and labeled peptide content are separate fields on a well-built listing rather than one merged figure. A listing that quotes only a container size has not told you the numerator.

The gap between nominal capacity and the volume you can practically add is the headspace a listing describes. Headspace is the reason a 3 mL blank does not take 3 mL of bacteriostatic water: the stopper displaces gas, and a vial filled to the brim pressurizes when you seat it.

How do you convert a vial claim into cost per mg and concentration?

Two arithmetic steps do all the work. Concentration in mg/mL is vial mg divided by mL of diluent added. Catalog cost per mg is list price divided by labeled vial mg. Neither depends on the nominal container size.

Vial (mg)	Catalog price (USD)	Cost per mg (USD)	+1.0 mL (mg/mL)	+2.0 mL (mg/mL)	+2.5 mL (mg/mL)
10	100	10.00	10.0	5.0	4.0
20	195	9.75	20.0	10.0	8.0

Concentration and catalog cost per mg for the two retatrutide vial sizes listed in the HEEZ catalog, prices as of September 2026 from the HEEZ catalog. Concentration = vial mg ÷ mL added; cost per mg = price ÷ vial mg. Diluent volumes are declared inputs, not a supplier specification.

The 20 mg vial is cheaper per milligram by $10.00 − $9.75 = $0.25/mg, a 2.5% difference on the 10 mg baseline. That is the nominal cost advantage. It survives contact with usable volume only if the residual you leave behind is the same absolute quantity in both vials, which it is not once concentration differs.

The declared diluent volumes above are the reader’s inputs; a listing does not set them. If you want the same math for a volume not shown, the bacteriostatic water volume worked for a 10 mg vial runs the same formula at other input values, and peptcalc will reproduce the division if you prefer to check it against a calculator.

What does the residual volume actually cost?

Residual is a fixed millilitre quantity determined by vial geometry and withdrawal technique, not a percentage. That is the whole reason it distorts comparisons: the same 0.10 mL left behind is 10% of a vial reconstituted with 1.0 mL and 4% of the same vial reconstituted with 2.5 mL.

mL of diluent added	0.05 mL residual	0.10 mL residual	0.15 mL residual
1.0	5.0%	10.0%	15.0%
2.0	2.5%	5.0%	7.5%
2.5	2.0%	4.0%	6.0%

Share of the reconstituted vial that stays behind, by declared residual volume. Residual share = residual mL ÷ mL added × 100. Residual figures are declared inputs for the calculation; no supplier listing states them.

Work it through on the 10 mg vial. Add 2.0 mL and the concentration is 10 ÷ 2.0 = 5 mg/mL. Leave 0.10 mL behind and you have stranded 0.10 × 5 = 0.5 mg, so recovered mass is 9.5 mg. Effective cost per mg becomes $100 ÷ 9.5 mg = $10.53, against the $10.00 nominal figure.

The 20 mg vial at the same 2.0 mL sits at 10 mg/mL, so the same 0.10 mL strands 0.10 × 10 = 1.0 mg and recovered mass is 19 mg. Effective cost is $195 ÷ 19 mg = $10.26, against $9.75 nominal. The 20 mg vial still wins by $10.53 − $10.26 = $0.27/mg, but it only wins because both vials were normalized to the same 2.0 mL. Reconstitute the 20 mg vial at 1.0 mL for a thicker 20 mg/mL solution and the same residual strands 2.0 mg, which is $195 ÷ 18 mg = $10.83/mg and puts it behind the 10 mg vial.

This is the position worth taking: usable volume comparisons are invalid unless both listings are normalized to the same diluent volume first. A supplier quoting a larger nominal vial has given you permission to add more water, and adding more water is what shrinks the residual penalty. The vial size is not the lever; the diluent volume is.

Which listing fields let you compute usable volume at all?

Run these in order against any two listings before comparing them. Each is a field that either exists on the page or does not.

1. Labeled peptide mass in mg. Without it, no concentration is computable. A container size in mL is not a substitute.
2. COA measured content against label. A measured value slightly above label is ordinary fill variance, which is what overfill on a vial specification actually describes; it is not spare material to build into your math.
3. Nominal container size in mL. Useful only as an upper bound on how much diluent the vial will accept.
4. Stated maximum recommended fill after reconstitution. Rare. When present, this is the closest a listing comes to a usable-volume claim.
5. Stopper and septum type. Determines hold-up on the stopper face and how many penetrations the closure tolerates.
6. Whether “deliverable” or “recoverable” volume appears anywhere. If a listing uses either word, check whether it names a test method. An unqualified “usable volume” claim with no method behind it is a marketing number.

Items 1 and 2 are the only two that constrain the numerator. Everything else constrains the denominator, and the denominator is under your control once the vial is open. Where a supplier publishes label mass, COA content and container spec as three distinct fields, as the retatrutide source listing does, the conversion above takes about a minute per listing. All of this is reference material for research use only.

How do the trial dose arms map onto draws per vial?

The phase 2 obesity trial enrolled 338 adults and tested once-weekly subcutaneous retatrutide at 1 mg, 4 mg, 8 mg and 12 mg against placebo for 48 weeks, reporting least-squares mean body weight change at 24 weeks of −7.2% in the 1 mg group and −17.5% in the 12 mg group versus −1.6% for placebo, per the 2023 NEJM phase 2 retatrutide obesity trial report. Those four amounts are the practical span a vial has to cover.

Weekly amount (mg)	From 10 mg + 2.0 mL (5 mg/mL)	From 20 mg + 2.0 mL (10 mg/mL)	Nominal draws, 20 mg vial	Draws at 1.90 mL usable
1	0.20 mL / 20 U	0.10 mL / 10 U	20	19
4	0.80 mL / 80 U	0.40 mL / 40 U	5	4.75
8	1.60 mL / 160 U	0.80 mL / 80 U	2.5	2.375
12	2.40 mL / 240 U	1.20 mL / 120 U	1.67	1.58

Volume occupied by each phase 2 dose arm at two declared reconstitution setups. Dose arms from the phase 2 obesity trial (PMID 37366315). Volume = amount mg ÷ concentration mg/mL; U-100 units = mL × 100; draws = usable mL ÷ volume per draw, with usable set to 2.0 − 0.10 = 1.90 mL.

Two consequences fall straight out of the table. A U-100 syringe holds 1.0 mL, so the 8 mg and 12 mg columns on the 10 mg vial at 5 mg/mL exceed one barrel fill; at 2.40 mL, the 12 mg amount exceeds the entire 2.0 mL reconstituted vial. And the fractional draws in the last column are where residual shows up as a real loss: 2.375 draws at 8 mg means the third draw delivers 0.375 of an 0.80 mL fill, which is 0.30 mL, or 3 mg at 10 mg/mL.

The lower end of the studied range is smaller still. The phase 2 type 2 diabetes trial randomized 281 participants across placebo, 1.5 mg dulaglutide and retatrutide maintenance amounts from 0.5 mg to 12 mg weekly, with change in HbA1c at 24 weeks as the primary endpoint and a −2.02% least-squares mean change in the 12 mg escalation arm against −0.01% for placebo, per the 2023 Lancet Diabetes & Endocrinology phase 2 trial in type 2 diabetes. A 0.5 mg amount from a 20 mg vial at 10 mg/mL is 0.05 mL, or 5 units, which is at the low end of what a U-100 barrel reads accurately.

Weekly subcutaneous administration is also the design of the phase 3 program: TRIUMPH comprises four randomized double-blind studies of weekly subcutaneous retatrutide against placebo in over 5800 participants, described in the TRIUMPH phase 3 program design paper. One draw per week is the interval any per-vial draw count is denominated in.

If a listing gives you only a nominal container size and a labeled mass, the field to request from the supplier is the batch fill weight on the COA record. That fixes the numerator before you choose a diluent volume, and it is the only figure on a specification sheet that a usable-volume claim can legitimately be built from.